Calcium Channel Blockers for Atrial Fibrillation: Verapamil & Diltiazem Dosing, Interactions, and Special Populations
Non-dihydropyridine calcium channel blockers (NDHP-CCBs)—verapamil and diltiazem—are first-line rate-control agents for atrial fibrillation (AFib). Dihydropyridines (amlodipine, nifedipine) are NOT used for rate control.
Mechanism in AFib
- Block L-type calcium channels in SA/AV nodes → ↓ automaticity, ↑ refractory period, ↓ conduction velocity.
- Effectively slow ventricular response at rest and during exercise.
- No direct effect on atrial fibrillation maintenance (unlike antiarrhythmics).
Drug Selection
| Drug | Formulations | Dosing (Rate Control) | Key Features |
|---|---|---|---|
| Verapamil | IR, SR, IV | PO: 80–120 mg TID (IR) or 120–480 mg daily (SR); IV: 2.5–5 mg bolus | More negative inotropy; constipation common; CYP3A4 substrate |
| Diltiazem | IR, ER, IV | PO: 60–120 mg TID (IR) or 120–540 mg daily (ER); IV: 0.25 mg/kg bolus + infusion | Less negative inotropy; preferred in mild HF; CYP3A4 substrate |
Contraindications and Cautions
- Absolute: Sick sinus syndrome (without pacemaker), 2nd/3rd degree AV block (without pacemaker), severe hypotension (SBP <90), cardiogenic shock.
- Relative: HFrEF (verapamil contraindicated; diltiazem cautious), severe hepatic impairment, concurrent strong CYP3A4 inhibitors (clarithromycin, azoles, HIV protease inhibitors) or inducers (rifampin, carbamazepine).
Key Drug Interactions
- Digoxin: Verapamil/diltiazem ↑ digoxin levels 50–75% → monitor levels.
- Beta-blockers: Additive AV node suppression → bradycardia, heart block. Use cautiously; monitor HR.
- Anticoagulants: Verapamil ↑ dabigatran (P-gp); diltiazem ↑ apixaban/rivaroxaban (CYP3A4/P-gp). Dose adjust per labeling.
- Statins: ↑ simvastatin/lovastatin/atorvastatin levels → myopathy risk. Prefer pravastatin/rosuvastatin.
- Grapefruit juice: Inhibits CYP3A4 → ↑ CCB levels.
Side Effects
- Constipation (verapamil > diltiazem), peripheral edema, headache, dizziness, flushing, gingival hyperplasia (verapamil), bradycardia, AV block.
- IV: Hypotension, asystole risk if bolus too fast.
Special Populations
- Pregnancy: Category C. Diltiazem preferred if needed (more data). Avoid 1st trimester if possible.
- Breastfeeding: Low milk transfer; generally compatible.
- Elderly: Start low; monitor for hypotension, bradycardia, constipation.
- HFrEF: Avoid verapamil; diltiazem may be used cautiously if rate control needed and beta-blocker maximized.
Monitoring
- Heart rate (target resting <110 bpm; individualized), blood pressure, ECG (PR interval), electrolytes, renal/hepatic function.
- Assess symptom control (palpitations, exercise tolerance).
CCBs are effective, well-tolerated rate-control options. Individualize choice based on comorbidities, interactions, and patient factors.
Ear Candling - Related Articles
- LT1 Engine Valve Adjustment: Is It Necessary for Your Gen II Small-Block?
- Scrubs for Occupational Therapists: Professional Attire Guidelines by Setting
- Patients vs. Patience: Homophones Explained with Examples
- Pill-Sized Drones in Medicine: Benefits and Risks
- The Cochlea: Structure, Function, and Its Role in Hearing and Balance
- Inner Ear Anatomy: Cochlea, Vestibular System, and Neural Pathways
- Ear Infection Symptoms: Fever, Vomiting, Diarrhea – What's Typical and What's Not
